<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To obtain background information on elderly <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), unselected data covering 159 patients aged 60 years or over with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> from 14 hospitals in Nagoya, Japan was analyzed retrospectively </plain></SENT>
<SENT sid="1" pm="."><plain>Among these patients, 119 had de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 32 had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> which evolved from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and 8 had other types of <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The survey showed that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> tended to be more prevalent in patients aged 70 years and older and that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> showed a significantly more severe degree of <z:hpo ids='HP_0001882'>leukopenia</z:hpo> and <z:hpo ids='HP_0001903'>anemia</z:hpo> than de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> also showed a significantly lower complete remission (CR) rate than that of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> [6.9% (2/29) vs 58.3% (67/11), P &lt; 0.01] and significantly shorter survival times than those of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> [median: 3.6 months vs 9.6 months, P &lt; 0.01 (generalized Wilcoxon test; GW] </plain></SENT>
<SENT sid="4" pm="."><plain>In de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, the proportion of patients treated with conventional therapy (CT group) decreased significantly, and that of those with attenuated therapy (AT group) increased significantly as age elevated (P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>The CT group showed a significantly higher CR rate (65.4% vs 41.2%, P &lt; 0.05) and a significantly longer survival period than those of the AT group [median: 11.6 months vs 4.8 months, P &lt; 0.05 (GW)] </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival rates of the older age groups became significantly shorter with aging [P &lt; 0.01 (GW)] </plain></SENT>
</text></document>